Everand Logo

Welcome to Everand!

  • STAT

    First CRISPR treatment for blood diseases shows early benefits in two patients

    The first two patients to receive a CRISPR-based treatment for inherited blood disorders have benefited from the experimental therapy, said the companies developing the therapy.
    by Sharon Begley and Adam Feuerstein Nov 19, 2019 5 minutes

    The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle cell disease and beta thalassemia have benefited from the experimental therapy and experienced only temporary and treatable side effects, the companies developing the treatment announced on Tuesday.

    The two patients, enrolled in a pair of ongoing clinical trials, have been free from blood transfusions and disease symptoms for a relatively short time, but the encouraging data offer hope that genome editing might one day offer a safe, durable cure for both blood diseases.

    The companies, CRISPR Therapeutics () and Vertex Pharmaceuticals, have competition. Last June, a one-time gene therapy for beta thalassemia from Bluebird Bio , with a U.S. approval expected next year. Several other companies and academic scientists are also pursuing curative treatments for beta thalassemia and sickle cell disease based on genome

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT1 min read
    STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
    Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks